View in EDS

Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.

Saved in:
Bibliographic Details
Title: Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.
Authors: Lopez JS; Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, London SW7 3RP, UK. Electronic address: juanita.lopez@icr.ac.uk., Milhem M; Department of Internal Medicine, Division of Hematology/Oncology and BMT, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Butler MO; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto M5G 2M9, ON, Canada; Departments of Medicine and Immunology, University of Toronto, Toronto M5G 2M9, ON, Canada., Thistlethwaite F; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M20 4GJ, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK., Van Tine BA; Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA., D'Angelo SP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA., Johnson ML; Lung Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN 37203, USA., Sato T; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA 19107, USA., Arkenau HT; Phase-1 Trials Unit, Sarah Cannon Research Institute, UCL Cancer Institute, University College London, London W1G 6AD, UK., Edukulla R; Biometrics, Immunocore, Gaithersburg, MD 20878 USA., Wustner J; Translational Medicine, Immunocore, Conshohocken, PA 19428 USA., Marshall S; Clinical Development, Immunocore, Gaithersburg, MD 20878 USA., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Apr 15; Vol. 6 (4), pp. 101994. Date of Electronic Publication: 2025 Mar 06.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40054461
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lopez+JS%22">Lopez JS</searchLink>; Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, London SW7 3RP, UK. Electronic address: juanita.lopez@icr.ac.uk.<br /><searchLink fieldCode="AU" term="%22Milhem+M%22">Milhem M</searchLink>; Department of Internal Medicine, Division of Hematology/Oncology and BMT, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.<br /><searchLink fieldCode="AU" term="%22Butler+MO%22">Butler MO</searchLink>; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto M5G 2M9, ON, Canada; Departments of Medicine and Immunology, University of Toronto, Toronto M5G 2M9, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Thistlethwaite+F%22">Thistlethwaite F</searchLink>; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M20 4GJ, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.<br /><searchLink fieldCode="AU" term="%22Van+Tine+BA%22">Van Tine BA</searchLink>; Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA.<br /><searchLink fieldCode="AU" term="%22D'Angelo+SP%22">D'Angelo SP</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.<br /><searchLink fieldCode="AU" term="%22Johnson+ML%22">Johnson ML</searchLink>; Lung Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN 37203, USA.<br /><searchLink fieldCode="AU" term="%22Sato+T%22">Sato T</searchLink>; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA 19107, USA.<br /><searchLink fieldCode="AU" term="%22Arkenau+HT%22">Arkenau HT</searchLink>; Phase-1 Trials Unit, Sarah Cannon Research Institute, UCL Cancer Institute, University College London, London W1G 6AD, UK.<br /><searchLink fieldCode="AU" term="%22Edukulla+R%22">Edukulla R</searchLink>; Biometrics, Immunocore, Gaithersburg, MD 20878 USA.<br /><searchLink fieldCode="AU" term="%22Wustner+J%22">Wustner J</searchLink>; Translational Medicine, Immunocore, Conshohocken, PA 19428 USA.<br /><searchLink fieldCode="AU" term="%22Marshall+S%22">Marshall S</searchLink>; Clinical Development, Immunocore, Gaithersburg, MD 20878 USA.<br /><searchLink fieldCode="AU" term="%22Rodon+J%22">Rodon J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101766894%22">Cell reports. Medicine</searchLink> [Cell Rep Med] 2025 Apr 15; Vol. 6 (4), pp. 101994. <i>Date of Electronic Publication: </i>2025 Mar 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101766894 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3791 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663791%22">26663791 </searchLink><i>NLM ISO Abbreviation: </i>Cell Rep Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40054461
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.xcrm.2025.101994
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 101994
    Titles:
      – TitleFull: Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lopez JS
      – PersonEntity:
          Name:
            NameFull: Milhem M
      – PersonEntity:
          Name:
            NameFull: Butler MO
      – PersonEntity:
          Name:
            NameFull: Thistlethwaite F
      – PersonEntity:
          Name:
            NameFull: Van Tine BA
      – PersonEntity:
          Name:
            NameFull: D'Angelo SP
      – PersonEntity:
          Name:
            NameFull: Johnson ML
      – PersonEntity:
          Name:
            NameFull: Sato T
      – PersonEntity:
          Name:
            NameFull: Arkenau HT
      – PersonEntity:
          Name:
            NameFull: Edukulla R
      – PersonEntity:
          Name:
            NameFull: Wustner J
      – PersonEntity:
          Name:
            NameFull: Marshall S
      – PersonEntity:
          Name:
            NameFull: Rodon J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 04
              Text: 2025 Apr 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3791
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cell reports. Medicine
              Type: main
ResultId 1